Tests VC005 tablets for moderate to severe atopic dermatitis in adults
Tests VC005 tablets against placebo in adults with moderate to severe atopic dermatitis.
Plain-language title generated from the registry record
Registry title: Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
Key facts
- Where
- Nanjing, ChinaSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 with moderate to severe atopic dermatitis (eczema) who did not respond well to skin treatments, or could not tolerate them.
- Age
- 18 to 75 years
- Sex
- Men and women
- Disease stage
- Moderate to severe atopic dermatitis, with symptoms for at least 1 year. The skin disease must meet set severity scores (EASI score ≥12, IGA score ≥3, or ≥10% of body surface involved).
- Earlier treatment
- Within the last year, a treatment applied to the skin did not work well enough or was not tolerated.
Main reasons for not taking part
- Cannot swallow the study drug, or has a stomach or bowel disease that affects drug absorption
- Current or past lymphoproliferative disorder, or any cancer within the last 5 years (with a few exceptions)
- Past blood clots, such as deep vein thrombosis or pulmonary embolism
- Herpes virus infection in the last month, or repeated shingles (2 or more episodes)
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06723080, who can take part
Where in China
- Chinese Academy of Medical Sciences Hospital for Skin DiseasesNanjing, ChinaContact: Jin NieTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Jiangsu vcare pharmaceutical technology co., LTD
- Trial code
- NCT06723080
- Record updated
- 27 July 2026
- Original description
This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical studyRead full original descriptionShow less
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study
Inclusion: (1）The patient understands and voluntarily signs the Informed Consent Form (ICF), and has the willingness and ability to complete the regular visits,treatment plans, laboratory tests and other experimental procedures required by the program. (2) Male or female patients aged ≥18 and ≤75 years at the time of signing the ICF. (3) Meet Hanifin-Rajka diagnostic criteria at screening and have atopic dermatitis （AD) symptoms for at least 1 year prior to baseline. (4) At screening and baseline, meets criteria for moderately severe AD based on the investigator's assessment of 3 of the following:Eczema area and severity index (EASI) score ≥12;Psoriasis Area Severity Index (IGA) score ≥3;AD involvement in ≥10% of the Body Surface Area (BSA). (5) Recent (within 1 year prior to screening) topical treatment for AD with inadequate or intolerant clinical response, as determined by the investigator.
Exclusion: (1) Inability to swallow the test drug or refractory nausea and vomiting, malabsorption, extracorporeal biliary shunt, or the presence of a gastrointestinal disorder (e.g., Crohn's disease, ulcerative colitis, or short bowel syndrome) or other malabsorption condition that interferes with the absorption of the drug; (2) Current or history of lymphoproliferative disorders or presence of signs or symptoms suggestive of possible lymphoproliferative disorders of lymphoid tissue, including lymphadenopathy or splenomegaly; malignancies of any kind, or a history of any malignancy within the 5 years prior to Screening (except for completely resected carcinoma in situ of the cervix or non-metastatic squamous cell or basal cell carcinoma of the skin or papillary carcinoma of the thyroid gland); (3) Patients with prior thromboembolism (including deep vein thrombosis, pulmonary embolism, arterial thrombosis, etc.) or other high-risk groups prone to thromboembolism; (4) Patients with a history of herpes virus infection within the last 1 month or those with recurrent episodes of herpes zoster (≥2), disseminated herpes zoster, disseminated herpes simplex, or those for whom herpes zoster or herpes simplex infections cannot be excluded at this time.